文献速递精神分裂症与精神病性障碍

精神分裂症阴性症状辅助治疗试验中效应量随样本量增加而缩减:跨作用机制的荟萃分析与荟萃回归

Effect Size Deflation With Increasing Sample Size in Adjunctive Trials for Negative Symptoms in Schizophrenia: A Meta-Analysis and Meta-Regression Across Mechanisms of Action.
PubMed 文献 · Am J Psychiatry · 2025-11-19

该荟萃分析与荟萃回归纳入159项活性-安慰剂对照比较(13,020例独特参与者),评估精神分裂症阴性症状辅助治疗试验中效应量是否随样本量增加而缩减。结果显示组间疗效随样本量和中心数增加而显著减小,主要源于安慰剂组改善更明显,而非活性治疗组。

要点

  • 组间阴性症状疗效随样本量增加而显著缩减(b=-0.60)。
  • 缩减主要源于安慰剂组改善更明显(b=-0.45),活性治疗组无显著变化。
  • 显著组间效应多见于≤150例、≤10个中心且招募密度>20例/中心的研究。

核心结论

  • 样本量增大时安慰剂组与活性治疗组反应出现差异缩放,可能提示中心管理问题导致大型试验阴性结果。

研究设计与样本

  • 对精神分裂症辅助作用机制随机临床试验进行荟萃分析与荟萃回归,纳入阴性症状结局。
  • 共识别8种作用机制,涵盖159项活性-安慰剂比较,13,020例独特参与者,59.2%为男性(SD=26.8),57.2%为多中心研究。

主要发现

  • 四种作用机制观察到阴性症状组间差异。
  • 组间治疗效应随样本量增加(b=-0.60)和中心数增加(b=-0.33)而显著减小。
  • 缩减主要归因于安慰剂组显著更大改善(b=-0.45,SE=0.21),活性治疗组无显著变化(b=0.14,SE=0.21)。
  • 显著组间效应优先见于≤150例参与者、≤10个中心且平均每中心>20例参与者(招募密度)的研究(b=-0.52)。

临床怎么用

  • 当前功效分析方法未充分考虑样本量依赖的效应量缩减,样本量或中心数增加及招募密度降低时II类错误风险过高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Meta-analytic evidence supports the effectiveness of several mechanisms of action adjunctive to antipsychotics for the treatment of negative symptoms in schizophrenia. Nevertheless, the results have not been replicated consistently in multicenter randomized clinical trials. The authors' primary objective in this study was to assess whether differential scaling of response in the placebo arm by sample size could account for the discrepant results between smaller- and larger-scale trials. METHODS: The authors conducted a meta-analysis and meta-regression of the potential contribution of differential scaling by sample size, site number, and other potential moderators in randomized clinical trials of adjunctive mechanisms of action in schizophrenia that included negative symptom outcomes. RESULTS: Eight mechanisms of action were identified across 159 active-placebo comparisons with 13,020 unique participants (59.2% male [SD=26.8]; 57.2% multicenter studies). Between-group differences in negative symptoms were observed for four mechanisms of action. The size of the between-group treatment effects decreased significantly with increasing sample size (b=-0.60) and site number (b=-0.33). This was attributable primarily to significantly greater improvement in the placebo arm (b=-0.45, SE=0.21), but not the active treatment arm (b=0.14, SE=0.21). Consequently, significant between-group effects were observed preferentially in studies with ≤150 participants and ≤10 sites, along with a mean of >20 participants per site ("recruitment density") (b=-0.52). CONCLUSIONS: This differential placebo-active scaling with increased sample size is unlikely to be of physiological origin and may indicate that site management issues contribute to negative clinical results in large-scale trials for the negative symptoms of schizophrenia. Current power analytic approaches do not adequately consider the consequences of sample size-dependent effect size deflation, leading to excessive risk of type II error with increasing sample size or site numbers and decreasing recruitment density.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kantrowitz JT, Mayer MR, Choo TH, et al. Effect Size Deflation With Increasing Sample Size in Adjunctive Trials for Negative Symptoms in Schizophrenia: A Meta-Analysis and Meta-Regression Across Mechanisms of Action. Am J Psychiatry. 2025. PMID: 41254842. doi:10.1176/appi.ajp.20250034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。